Ixekizumab‐induced urticarial drug eruption

Abstract

Abstract Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL‐17A, which exhibited high efficacy against psoriasis. Although there are a limited number of cutaneous adverse reactions, biologic‐induced type I allergic reactions are rare. Herein, we report a case of ixekizumab‐induced urticaria.